Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment
携带 p53 突变(而非野生型 p53)的患者来源肿瘤类器官对 PARP 抑制剂的协同联合治疗敏感。
期刊:Cancer Letters
影响因子:10.1
doi:10.1016/j.canlet.2024.216608
Madorsky Rowdo, Florencia P; Xiao, Gu; Khramtsova, Galina F; Nguyen, John; Martini, Rachel; Stonaker, Brian; Boateng, Richard; Oppong, Joseph K; Adjei, Ernest K; Awuah, Baffour; Kyei, Ishmael; Aitpillah, Frances S; Adinku, Michael O; Ankomah, Kwasi; Osei-Bonsu, Ernest B; Gyan, Kofi K; Altorki, Nasser K; Cheng, Esther; Ginter, Paula S; Hoda, Syed; Newman, Lisa; Elemento, Olivier; Olopade, Olufunmilayo I; Davis, Melissa B; Martin, M Laura; Bargonetti, Jill